BioAtla Corp - Rasio nilai perusahaan marang dodolan BCAB

Simbol resmi perusahaan BioAtla Inc (BCAB)

BioAtla, Inc. (BCAB) growth is driven by breakthroughs in next-generation antibody development and merger prospects. The company's EV/Sales multiple confirms this trend, where the 848.24 level indicates the state of the parameter. Business efficiency is based on outsourcing production and testing to external partners. Meanwhile, research capacities operate strictly on schedule, ensuring the uninterrupted release of complex drugs through contract manufacturing plants.

BioAtla (BCAB): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 06.09.2026

BioAtla - rincian analitis lan metrik utama (BCAB)

- rega lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:BCAB, BioAtla Corp
Produk sing diprodhuksi bioatla.com

The current EV/Sales trend reflects market confidence in the targeted therapy potential of BioAtla, Inc. (BCAB) within the oncology segment. This multiple compares the total enterprise value (market capitalization plus net debt) to annual revenue, allowing for an assessment of the asset's investment attractiveness regardless of debt load, which is critical for evaluating the efficiency of innovative biologic drug development.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CHRS (Coherus BioSciences Inc.)|CRBP: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cardiff Oncology Corp (CRDF)|Rasio nilai perusahaan marang pendapatan BeyondSpring|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales